



Stéphane Bancel, Chief Executive Officer  
Moderna, Inc.  
200 Technology Square  
Cambridge, MA 02139

November 16, 2021

Dear Mr. Bancel,

We are writing to urge you to accelerate efforts to end the pandemic around the world. Moderna's world-class vaccine offers you the unparalleled power to help save millions of lives across the world from this deadly disease in the near future. Yet Moderna has taken a different approach so far: mRNA-1273 has so far almost exclusively been supplied to wealthy countries, while low- and middle-income countries are left without, or with long waits and high prices.

Humanity remains in a state of emergency. Almost a year since the world's first vaccine was administered, only four percent of people have received a vaccine in low-income countries, which have received less than half of one percent of vaccines globally. We are in no doubt that most COVID-19 deaths in low-income countries are now avoidable deaths: lives that could be saved were effective vaccines, none more than mRNA-1273, widely available to their populations. Concerningly, the World Health Organization estimates that six of every seven COVID-19 cases in Africa are going undetected.

We believe Moderna can help solve this crisis by ensuring that mRNA-1273 is produced and delivered safely at scale. On October 13, at a panel event hosted virtually by Yale Law School, Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team, stated that "there is very substantial capacity through 2022 for [Moderna] to close, and in fact, even exceed the COVAX gap and they need to do that." Dr. Kessler added that this capacity was "in the billions at Moderna through 2022," and called on Moderna to provide these doses to low- and middle-income countries at a not-for-profit price.

Moreover, the White House on October 18 called on Moderna to share know-how with other parts of the world to increase vaccine manufacturing capacity. On October 26, Moderna announced plans to sell up to 110 million doses to the African Union, with only 15 million doses arriving before the end of 2021, and 35 million more doses arriving during the first quarter of 2022.

If these plans are realized, more than 50 million Africans could be vaccinated. But 1.3 billion people live on the continent. The strategy of relying on donations to overcome a global pandemic is failing. We write on behalf of nearly 90 health, human rights and humanitarian organizations in the US and across the globe including UNAIDS, Club de Madrid, Public Citizen and Oxfam to ask for an urgent response on three issues fundamental to ramping up supply.

1) The NIH-Moderna COVID-19 vaccine is the first Moderna ever marketed, and Moderna has produced fewer than 500 million doses cumulatively so far. Does Moderna have excess production capacity “in the billions [of doses] through 2022” that could be allocated towards low- and middle-income countries, as Dr. Kessler has stated? Please provide detailed justification of Moderna’s production estimates, including a breakdown of how many 100 µg (primary series dose) and 50 µg (booster dose) you expect to manufacture and how prior production estimates throughout this pandemic have borne out.

2) The World Health Organization is establishing a technology transfer hub in South Africa to produce mRNA-1273 – or a vaccine as close to it as possible. The WHO has stated that Moderna transferring its technology would shave years off their production timeline. Will Moderna heed the call of Dr. Kessler, the White House and WHO to share know-how and transfer technology through the World Health Organization to qualified manufacturers in other parts of the world?

3) So far, only about one million doses of mRNA-1273 have gone to low-income countries and Moderna has shipped a greater share of doses to wealthy countries than any other COVID-19 vaccine manufacturer. Our analysis suggests that at scale, a not-for-profit price for mRNA-1273 would be no greater than \$3 per dose. Will Moderna commit to providing the doses that it produces to low- and middle-income countries where they are needed most, including through COVAX, and at cost?

Moderna, with the NIH, has developed the world’s most effective vaccine technology, that is also the world’s most exclusive vaccine, out of reach to billions of people. This can and must change.

We look forward to your urgent response and stand ready to work with you to scale up vaccine supply, save lives and end this pandemic.

Sincerely,

People's Vaccine Alliance  
Public Citizen  
Africa Faith and Justice Network  
African Alliance  
African Women and Youth Initiative  
American Friends Services Committee  
American Medical Student Association  
Amnesty International  
Amref Health Africa UK  
Archewell Foundation  
AVAC  
Be A Hero  
Bread for the World  
C19 Peoples Coalition and Peoples Vaccine Campaign South Africa  
CAFOD (Catholic Agency for Overseas Development)

Center for Artistic Activism  
Center for Economic and Social Rights  
Center for Health and Hope  
Chasing Zero  
Christian Aid  
Clean Clothes Campaign International Office  
Club de Madrid  
Concern Worldwide  
Congregation of Our Lady of Charity of the Good Shepherd, U.S. Provinces  
Conigli Bianchi - Artivists against Serophobia  
Doctors For America  
Doctors Without Borders | Médecins Sans Frontières USA  
EMERGENCY  
EqualHealth Campaign Against Racism  
European Citizens' Initiative No profit on Pandemic  
Faithful America  
Foundation for Integrative AIDS Research (FIAR)  
Free the Vaccine for COVID-19  
Freedom Road  
Friends in Solidarity, Inc.  
Frontline AIDS  
Fundación IFARMA  
Get1Give1 Worldwide  
Global Justice Now  
Global Network of People living with (GNP+)  
Health GAP  
Health Poverty Action  
HelpAge International  
Help Justice International  
Human Rights Watch  
Humana People to People  
Ibn Sina Academy of Medieval Medicine and Sciences  
Incentives for Global Health  
International Trade Union Confederation  
Just Treatment  
Kamukunji Paralegal Trust (KAPLET)  
Knowledge Ecology International  
Last Mile Health  
Leadership Conference of Women Religious  
Maryknoll Office for Global Concerns  
MSI United States  
National Advocacy Center of the Sisters of the Good Shepherd  
Network Lobby for Catholic Social Justice  
Nizami Ganjavi International Center  
ONE Campaign  
Oxfam  
Partners In Health

Physicians for Human Rights  
PrEP4All  
Public Eye, Switzerland  
Public Services International  
RESULTS  
RESULTS UK  
Right2Health Action  
Salud por Derecho  
Sama  
SECTION27  
Sojourners  
STOPAIDS  
The Access Challenge  
The Borgen Project  
The Center for Artistic Activism / Free the Vaccine for COVID-19  
The United Methodist Church - General Board of Church and Society  
Treatment Action Group  
UNAIDS  
UNI Global Union  
Unitarian Universalist Service Committee  
Universities Allied for Essential Medicines (UAEM)  
Vaccine Advocacy Resource Group  
Wemos  
Win Without War  
Youth Foundation of Bangladesh  
Yunus Centre

CC: Dr. David Kessler, Chief Science Officer, White House COVID-19 Response Team

**Moderna Board Members**

Noubar Afeyan, Ph.D., Co-founder and Chairman, Moderna; CEO, Flagship Pioneering  
Stephen Berenson, Managing Partner, Flagship Pioneering  
Sandra Horning, M.D., Co-founder and Advisor, EQRx  
Robert Langer, Sc.D., Academic Co-Founder, Moderna; David H. Koch Institute  
Professor, MIT  
Elizabeth (Betsy) Nabel, M.D., Executive Vice President for Strategy at ModeX  
Therapeutics  
François Nader, M.D., Former President, CEO and Executive Director, NPS  
Pharmaceuticals  
Paul Sagan, Senior Advisor and Executive-in-Residence, General Catalyst  
Elizabeth Tallett, Former Principal, Hunter Partners

**Moderna Top Institutional Shareholders**

Andrew Telfer, CEO, Baillie Gifford and Company  
Noubar Afeyan, CEO, Flagship Pioneering Inc.  
Mortimer J. Buckley, CEO, Vanguard Group, Inc. (The)

Larry Fink, CEO, Blackrock Inc.  
James P. Gorman, CEO, Morgan Stanley  
Ronald P. O'Hanley, CEO, State Street Corporation  
Abigail Johnson, CEO, FMR, LLC  
Philippe Laffont, CEO, Coatue Management, LLC  
Patrick Degorce, CEO, Theleme Partners, LLP  
Stephen Frank Mandel, CEO, Lone Pine Capital, LLC